Home › NDC Lookup › RxCUI directory › RxCUI 1043048

Bismuth subsalicylate 35 MG/ML Oral Suspension [Kaopectate Reformulated Aug 2006] — RxCUI 1043048

RxNorm drug concept · Semantic branded drug
RxCUI 1043048 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1043048
Official nameBismuth subsalicylate 35 MG/ML Oral Suspension [Kaopectate Reformulated Aug 2006]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asKaopectate Reformulated Aug 2006 35 MG/ML Oral Suspension; Kaopectate Extra Strength 525 MG in 15 mL Oral Suspension, Reformulated Aug 2006; Kaopectate 525 MG per 15 ML Oral Suspension, Reformulated Aug 2006
FDA products mapped2
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Bismuth Subsalicylate: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It relieves diarrhea, including traveler's diarrhea. It also helps with upset stomach after overindulging in food and drink, such as heartburn, indigestion, nausea, gas, belching a...
  • Use it only until the diarrhea stops, and no more than 2 days. If you're not better by then, or you get worse sooner, stop and see a doctor. Drink plenty of clear fluids while you...
  • That's a known, temporary and harmless effect of this medicine. But black stool can also signal bleeding, so do not use it if you already have bloody or black stool.
  • Children under 12 should be checked by a doctor first. Children and teens who have or are recovering from chicken pox or flu-like symptoms should not use it because of Reye's syndr...
📖 Read our full Bismuth Subsalicylate guide →

🕸️ Concept Web — How Bismuth subsalicylate 35 MG/ML Oral Suspension [... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Bismuth subsalicylate 35 MG/ML Oral Suspension [Kaopectate Reformulated Aug 2006] RxCUI 1043048

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Bismuth subsalicylate 19478
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Kaopectate Reformulated Aug 2006 659118
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Bismuth subsalicylate Oral Suspension 371100
    • Bismuth subsalicylate Oral Liquid Product 1161838
    • Bismuth subsalicylate Oral Product 1161839
    • Bismuth subsalicylate Oral Suspension [Kaopectate Reformulated Aug 2006] 642345
    • Kaopectate Reformulated Aug 2006 Oral Liquid Product 1169276
    • Kaopectate Reformulated Aug 2006 Oral Product 1169277
    • Oral Suspension 316969
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Bismuth subsalicylate 35 MG/ML Oral Suspension SCD · 308763
  • Bismuth subsalicylate 35 MG/ML SCDC · 315493
  • Bismuth subsalicylate Oral Suspension SCDF · 371100
  • Bismuth subsalicylate Oral Liquid Product SCDG · 1161838
  • Bismuth subsalicylate Oral Product SCDG · 1161839

Brand-Name Concepts

  • Bismuth subsalicylate 35 MG/ML [Kaopectate Reformulated Aug 2006] SBDC · 1043047
  • Bismuth subsalicylate Oral Suspension [Kaopectate Reformulated Aug 2006] SBDF · 642345
  • Kaopectate Reformulated Aug 2006 Oral Liquid Product SBDG · 1169276
  • Kaopectate Reformulated Aug 2006 Oral Product SBDG · 1169277
  • Kaopectate Reformulated Aug 2006 BN · 659118

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 1043048 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
55505-0200-36 236 mL in 1 BOTTLE (55505-200-36) Kaopectate Max Peppermint Flavor Anti Diarrheal Kramer Laboratories 2020-11-01
55505-0229-64 325 mL in 1 BOTTLE (55505-229-64) Kaopectate KRAMER LABORATORIES 2026-02-01
Observed labelers: KRAMER LABORATORIES (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.